img

Dr. Jyothi S Prabhu

  • Associate Professor
  • jyothi@sjri.res.in
About

  • Over the past decade as a molecular pathologist, Dr Jyoti S Prabhu has been a core member of a team which has assembled and followed-up a cohort of 450 breast cancer patients for 9 years with a loss to follow up of less than 5%. This project was funded primarily by long-term philanthropic grants and was designed not only to identify the molecular alterations in breast cancer specimens from Indian women, but also look into the demographic and psycho social aspects of the problem. In addition to a detailed documentation of the demographic, histological, clinical and laboratory information, including long-term outcomes, they have established a bio-bank comprising formalin fixed tumor tissue and blood specimens from subjects enrolled in the study after appropriate informed consent and ethical approval. The patients in this cohort were enrolled from 3 tertiary care centres by establishing stable working relationships with surgical and medical oncologists and onco-pathologists. The cohort has a median follow up of more than 72 months. They have estimated the levels of many dozens of molecular markers and examined their correlations to prognosis and response to therapy. As a consequence of this study, they have standardized all of the techniques for performing molecular analyses on nucleic acids and proteins, derived from formalin fixed material. Detailed examination of the data from this cohort has further confirmed the observations reported on pattern of breast cancer in Indian women and showed that though the proportional distribution of hormone receptor negative and triple negative breast cancer is higher in India, the clinical and biological behaviour of a specific subtype is no different from that reported from elsewhere in the world.

    Her current project is an extension of this work with specific focus on premenopausal breast cancer. The broad objective of this proposal is to find a clinical approach towards minimizing the risk of recurrence of breast cancer in premenopausal women. She proposes to identify the key pathways activated by the interaction of circulating hormones with their cognate nuclear receptors that in addition to estrogen and progesterone includes androgens, glucocorticoids and vitamin D. Their hypothesis is that the cross-talk of hormonally activated pathways in the background of high levels of circulating sex steroids in premenopausal women influences the development of therapeutic resistance in distinct ways.

Education

  • 2011 - 2015; PhD - Molecular Medicine
    St. John’s Medical College , Rajiv Gandhi University of Health Sciences
  • 1998 - 2000; Diploma in Clinical Pathology (DCP)
    Bangalore Medical College, Rajiv Gandhi University of Health Sciences
  • 1989 - 1995, Medicine
    MRMC, Gulbarga University
Experience

  • Associate Professor
    St. John’s Research Institute
    2016 - till date
    Bangalore, India
  • Assistant Professor
    St. John’s Research Institute
    2007 - 2016
    Bangalore, India
  • Pathologist – Incharge of Molecular Pathology Laboratory
    Triesta Sciences
    2004 - 2007
    Bangalore, India
  • Research Associate
    National Institute for Research in Reproductive Health
    2003 - 2004
    Mumbai, India
  • Pathologist
    Inlaks Hospital
    2002 - 2003
    Mumbai, India
  • Clinical Pathologist
    Jivraj Mehtha Hospital
    2000 - 2001
    Ahmedabad, India
Publications

Priya S, Kaur E, Kulshrestha S, Pandit A, Gross I, Kumar N, Agarwal H, Khan A, Shyam R, Bhagat P, Prabhu JS. CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors. Journal of Cell Science. 2021 Jul 19. (IF: 5.285)

Rajarajan S, Korlimarla A, Alexander A, Anupama CE, Ramesh R, Srinath BS, Sridhar TS, Prabhu JS. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes. Frontiers in endocrinology. 2021:716. (IF:5.555)

Nair MG, Prabhu JS, Sridhar TS. High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. Cancer treatment and research communications. 2021 Jan 1;27:100321. (Cite score- 1.2)

Lipsa A, Prabhu JS. Gender disparity in COVID-19: Role of sex steroid hormones. Asian Pacific journal of tropical medicine. 2021;14(1):5. (IF:2.285)

Nair MG, Somashekaraiah VM, Ramamurthy V, Prabhu JS, Sridhar TS. miRNAs: Critical mediators of breast cancer metastatic programming. Experimental Cell Research. 2021 Feb 17:112518. (IF: 3.905)

Crasta J, Ravikumar G, Rajarajan S, Gali S, Kulkarni KA, Vallikad E, Prabhu J. Expression of HER2 and EGFR Proteins in Advanced Stage High-grade Serous Ovarian Tumors Show Mutual Exclusivity. International Journal of Gynecological Pathology. 2021 Jan 1;40(1):49-55. (IF:2.762)

Rajarajan S, Jose B, Correa M, Sengupta S, Prabhu JS. Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1. Molecular and clinical oncology. 2020 Nov 1;13(5):1-. (Cite score- 1.63)

Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, PS H, Kaul R, Alexander A, Raghavan R, BS S, TS S. miR?18a activates Wnt pathway in ER?positive breast cancer and is associated with poor prognosis. Cancer medicine. 2020 Aug;9(15):5587-97.(IF:4.452)

Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, PS H, Kaul R, Alexander A, Raghavan R, BS S, TS S. miR?18a activates Wnt pathway in ER?positive breast cancer and is associated with poor prognosis. Cancer medicine. 2020 Aug;9(15):5587-97. (IF:4.452)

Ravikumar G, Crasta J, Prabhu JS, Thomas T, Dwarkanath P, Thomas A, Kurpad AV, Sridhar TS. CD15 as a marker of fetoplacental endothelial immaturity in IUGR placentas. The Journal of Maternal-Fetal & Neonatal Medicine. 2019 May 19;32(10):1646-53. (IF: 1.737)

Alexander A, Kaluve R, Prabhu JS, Korlimarla A, Srinath BS, Manjunath S, Patil S, Gopinath KS, Sridhar TS. The impact of breast cancer on the patient and the family in Indian perspective. Indian journal of palliative care. 2019 Jan;25(1):66. (IF:1.8)

Ravikumar G, Crasta J, Prabhu JS, Thomas T, Dwarkanath P, Thomas A, Sridhar TS, Kurpad AV. Eccentric placentae have reduced surface area and are associated with lower birth weight in babies small for gestational age. Journal of developmental origins of health and disease. 2018 Jun;9(3):281-6. (IF: 2.08)

Sucharita S, Ashwini V, Prabhu JS, Avadhany ST, Ayyar V, Bantwal G. The role of circulating microRNA in the regulation of beta cell function and insulin resistance among Indians with type 2 diabetes. Indian journal of endocrinology and metabolism. 2018 Nov;22(6):770. (IF: 1.21)

Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, CE Anupama, Alexander A, Kaluve RS, Manjunath S, Correa M, Srinath BS, Patil S, Kalamdani A, Prasad M, Sridhar TS. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumour Biol. 2017 Mar;39(3):1010428317695028. (IF: 3.05)

Nair MG, Desai K, Prabhu JS, Hari PS, Remacle J, Sridhar TS. Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes. Data in brief. 2016 Sep 1;8:944-7. (cite score: 1.7)

Nair MG, Desai K, Prabhu JS, Hari PS, Remacle J, Sridhar TS. ?3 integrin promotes chemoresistance to epirubicin in MDA-MB-231 through repression of the pro-apoptotic protein, BAD. Experimental Cell Research. 2016;346(1):137-45. (IF: 3.905)

Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G, Kumar RV, Manjunath S, Correa M, Srinath BS, Patil S, Prasad MS, Gopinath KS, Rao RN, Violette SM, Weinreb PH, Sridhar TS. High expression of integrin ?6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers. Cancer Medicine. 2016 Aug;5(8):2000-11. (IF:4.452)

Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E Anupama, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS. Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer. PLoS One. 2016 Apr 14;11(4):e0153113. (IF:3.240)

Mukherjee G, Lakshmaiah KC, Vijayakumar M, Prabhu JS, Telikicherla D, Sridhar TS, Kumar RV. Analysis of Clinico-Pathological Characteristicsof Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. J Integr Oncol. 2016; 5: 159.

Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, Dendukuri N, Manjunath S, Correa M, Raman N, Kalamdani A, Prasad M, Gopinath KS, Srinath BS, Sridhar TS. A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. J Cancer. 2014 Jan 23;5(2):156-65. (IF: 4.207)

Korlimarla A, Prabhu JS, Anupama CE, Remacle J, Wahi K, Sridhar TS. Separate quality-control measures are necessary for estimation of RNA and methylated DNA from formalin-fixed, paraffin-embedded specimens by quantitative PCR. J Mol Diagn. 2014 Mar;16(2):253-60. (IF: 5.568)

Korlimarla A, Bhandary L, Prabhu JS, Shankar H, Sankaranarayanan H, Kumar P, Remacle J, Natarajan D, Sridhar TS. Identification of a non-canonical nuclear localization signal (NLS) in BRCA1 that could mediate nuclear localization of splice variants lacking the classical NLS. Cell Mol Biol Lett. 2013 Jun;18(2):284-96. (IF: 5.787)

Prabhu JS, Wahi K, Korlimarla A, Correa M, Manjunath S, Raman N, Srinath BS, Sridhar TS. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour Biol. 2012 Apr;33(2):315-23. (IF: 3.05)

Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS. Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian J Surg Oncol. 2011 Jun;2(2):122-5. (IF: 0.205)

Sahoo R, Banerjee A, Payal K, Wani S, Korlimarla A, Babu VC, Prabhu JS. Improved method for detection of methylation status of genes from limited archived, FFPE and FNAC samples. Journal of Clinical and Diagnostic Research. 2009 June; 3:1493-1499. (Cite Score :0.82)

Prabhu JS, Korlimarla A, Banerjee A, Wani S, K P, Sahoo R. Gene-specific methylation: potential markers for colorectal cancer. Int J Biol Markers. 2009 Jan-Mar;24(1):57-62. (IF: 2.659)

Prabhu JS , Wani S, Korlimarla A, Payal K, Victor JM, Anand A, Sahoo R. qRT-PCR Compliments Immunohistochemistry In Archival Breast Cancer Samples. Journal of Clinical and Diagnostic Research. 2008 Aug ;( 2)963-968. (Cite Score :0.82)

Pandey V, Prabhu JS, Payal K, Rajan V, Deepak C, Barde S, Jagannath P, Borges A, Sridhar TS. Asessment of microsatellite instability in colorectal carcinoma at an Indian centre. Int J Colorectal Dis. 2007 Jul;22(7):777-82. (IF: 2.571)

Projects

Dept of Biotechnology- Wellcome-2019 grant titled 1"Breast Cancer in Pre-menopausal women- Evaluation of the role of steroid hormones in resistance to therapy" 2019-2024. Role: Lead Fellow.

RGUHS Research project Grant- MicroRNA expression profile in Mycosis fungoides and its distinction from inflammatory mimics. 2018-2020. Role: Co-Investigator.

RGUHS Research project Grant- Circulating microRNA, a novel prognostic and diagnostic biomarker of prediabetes, Type 2 diabetes and its complications among Indians. 2018-2020. Role: Co-Investigator.

RGUHS Research project Grant- A study to evaluate the Vit D receptors and their signaling pathways in skeletal muscle among Indians with type 2 diabetes. 2018-2020. Role: Co-Investigator.

DBT-UOE titled “Investigating the role of BLM Helicase as a global tumor suppressor: Understanding its regulatory loops and using the knowledge for therapeutic and clinical applications in cancer biology”. Co- Ordinator: Sagar Sengupta, NII, New Delhi, 2015-2019. Role: Co-Principal Investigator.

RGUHS Research project Grant - Expression of human epithelial growth factor (HER) family of proteins in ovarian serous carcinomas and their relation to clinicopathological factors.2016-2018. PI: Julian Crasta, Dept of Pathology, SJMC, Bangalore. Role: Co-Investigator.

DBT BBI (Bioengineering Biodesign Initiative) Grant. Examination of mechaniobiology of ER negative breast cancer tumors in Indian women 2011-2016. Role: Co-Investigator.

Patents

Rashmita Sahoo, Payal K, Arindam Banerjee, Shivangi Wani, Aruna Korlimarla, V. Chittibabu, Jyothi S. Prabhu, 2013. An improved method of Bisulphite modification of DNA from limited archived formalin fixed paraffin embedded (FFPE) and fine needle aspirate cytology samples. Indian Patent 257496 filed 13 Feb 2008 and issued 8 Oct 2013.

Sridhar TS, Jyothi S Prabhu, Aruna Korlimarla, Jose remacle, 2015. Method for identification of Deficient BRCA function - Patent application filed Ref No. BPREMA0001IN00.

Groups and Associations

  • Member
    KCIAPM
  • Member
    IAPM
  • Member
    ESMO
Interests

Cohort and biorepository building; Integration of clinical and molecular Pathology; Breast cancer gene expression profiling; Patient clinical follow up; Characterization of intratumor genetic heterogeneity in breast cancers.

Attachments